ScholarLens Back to search
2010•Zhongguo yaofangRequires access

Clinical Observation of Moxifloxacin Versus Ceftriaxone Combined with Azithromycin in the Treatment of Community Acquired Pneumonia

Chai Wen-shu

Open publisher page 1 citations

Abstract

OBJECTIVE:To evaluate the clinical efficacy and safety of moxifloxacin versus ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.METHODS:60 patients with community acquired pneumonia were enrolled in randomized controlled study and randomly divided into 2 groups.Trial group were given moxifloxacin 0.4g once a day(i.v..) Control group were given ceftriaxone 3.0 g and azithromycin 0.5 g once a day(i.v..) The total duration of therapy was 7～10 days in both groups.RESULTS:After treatment,There was no statistical differences between 2 groups in respect of therapeutic effect,bacterium clearance rate and safety(P0.05.) CONCLUSION:Moxifloxacin is effective and safe as ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.

About this research paper

What this paper is about

OBJECTIVE:To evaluate the clinical efficacy and safety of moxifloxacin versus ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.METHODS:60 patients with community acquired pneumonia were enrolled in randomized controlled study and randomly divided into 2 groups.Trial group were given moxifloxacin 0.4g once a day(i.v..) Control group were given ceftriaxone 3.0 g and azithromycin 0.5 g once a day(i.v..) The total duration of therapy was 7～10 days in both groups.RESULTS:After treatment,There was no statistical differences between 2 groups in respect of therapeutic effect,bacterium clearance rate and safety(P0.05.) CONCLUSION:Moxifloxacin is effective and safe as ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE:To evaluate the clinical efficacy and safety of moxifloxacin versus ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.METHODS:60 patients with community acquired pneumonia were enrolled in randomized controlled study and randomly divided into 2 groups.Trial group were given moxifloxacin 0.4g once a day(i.v..) Control group were given ceftriaxone 3.0 g and azithromycin 0.5 g once a day(i.v..) The total duration of therapy was 7～10 days in both groups.RESULTS:After treatment,There was no statistical differences between 2 groups in respect of therapeutic effect,bacterium clearance rate and safety(P0.05.) CONCLUSION:Moxifloxacin is effective and safe as ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia.

Key concepts: Azithromycin, Ceftriaxone, Moxifloxacin, Medicine, Community-acquired pneumonia, Pneumonia, Internal medicine, Randomized controlled trial

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Observation of Moxifloxacin Versus Ceftriaxone Combined with Azithromycin in the Treatment of Community Acquired Pneumonia — Research Paper | ScholarLens